GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Intrinsic Value: Projected FCF

Cell Source (Cell Source) Intrinsic Value: Projected FCF : $-1.19 (As of May. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cell Source Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-28), Cell Source's Intrinsic Value: Projected FCF is $-1.19. The stock price of Cell Source is $0.0008. Therefore, Cell Source's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Cell Source's Intrinsic Value: Projected FCF or its related term are showing as below:

CLCS's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.29
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Cell Source Intrinsic Value: Projected FCF Historical Data

The historical data trend for Cell Source's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source Intrinsic Value: Projected FCF Chart

Cell Source Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.87 -1.00 -1.19 -1.04 -1.15

Cell Source Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.12 -1.15 -1.16 -1.21 -1.19

Competitive Comparison of Cell Source's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Cell Source's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell Source's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Cell Source's Price-to-Projected-FCF falls into.



Cell Source Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Cell Source's Free Cash Flow(6 year avg) = $-2.66.

Cell Source's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep23)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-2.66352+-16.03/0.8)/38.192
=-1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cell Source  (OTCPK:CLCS) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Cell Source's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0008/-1.188603552652
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cell Source Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Cell Source's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cell Source (Cell Source) Business Description

Industry
Traded in Other Exchanges
N/A
Address
57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Executives
George Verstraete director 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave director, 10 percent owner 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner 10 percent owner
Yoram Drucker director 31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown director 100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat director, officer: CEO and CFO C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty director C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman director, 10 percent owner C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433

Cell Source (Cell Source) Headlines